156.44
[1]. Pérez-Trallero E, et, al. Prediction of in-vivo efficacy by in-vitro early bactericidal activity with oral beta-lactams, in a dose-ranging immunocompetent mouse sepsis model, using strains of Streptococcus pneumoniae with decreasing susceptibilities to penicillin. J Chemother. 2001 Apr;1(2):118-25.
[2]. Valentini S, et, al. In-vitro evaluation of cefpodoxime. J Antimicrob Chemother. 1994 Mar;():495-508.
[]. Werner H, et, al. Comparative in vitro activity of cefpodoxime against anaerobes other than Bacteroides fragilis. Infection. 1991 Sep-Oct;19(5):-9.
[4]. Akihiro Nakamura, et al. Analysis of molecular epidemiologic characteristics of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli colonizing feces in hospital patients and community dwellers in a Japanese city. J Infect Chemother. 2016 Feb;22(2):2-.
[5]. Arijit Ghosh, et al. Comparison of the effectiveness and safety of cefpodoxime and ciprofloxacin in acute exacerbation of chronic suppurative otitis media: A randomized, open-labeled, phase IV clinical trial. J Pharmacol Pharmacother. 2012 Oct;(4):20-4.
H1-H4
P261-P22-P280-P284-P02+P52-P04+P40-P62+P64-P501